

AMENDMENT

1-11 (Canceled).

12. (Original) A method of treating Tourette's Syndrome in a human in need thereof, the method comprising administering to the human with Tourette's syndrome, a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine, the amount being sufficient to decrease the signs and symptoms of Tourette's Syndrome.

13. (Original) The method of claim 12 wherein exo-R-mecamylamine is administered intravenously, transdermally, intrathecally, orally or by bolus injection.

14. (Original) The method of claim 12, wherein the amount is about 0.5 mg to about 20 mg.

15. (Original) The method of claim 12, wherein exo-R-mecamylamine is administered one to four times per day.

16. (Currently amended) A method of treating a human with a neuropsychiatric ~~disorders~~ disorder, the method comprising administering to the human in need thereof, a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine, the amount being sufficient to decrease the signs and symptoms of the neuropsychiatric disorder.

17. (Original) The method of claim 16 wherein the neuropsychiatric disorder is bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder.

18. (Original) The method of claim 16 wherein exo-R-mecamylamine is administered intravenously, transdermally, intrathecally, orally or by bolus injection.

19. (Original) The method of claim 16, wherein the amount is about 0.5 mg to about 20 mg.

20. (Original) The method of claim 16, wherein exo-R-mecamylamine is administered one to four times per day.